Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age, affecting roughly 8–13% of women worldwide. It manifests through irregular menstrual cycles, hyperandrogenism, and metabolic disturbances — often making conception difficult.
What causes PCOS?
The underlying mechanisms involve insulin resistance, elevated luteinizing hormone (LH), and increased ovarian androgen production. Genetics, lifestyle, and environmental factors all play a role.
Modern treatment paths
- Myo-Inositol + D-Chiro-Inositol in a 40:1 ratio has shown improvement in ovulation rates and insulin sensitivity.
- Combined oral contraceptives like Drospirenone + Ethinylestradiol help regulate cycles and reduce androgenic symptoms.
- Letrozole and Clomiphene remain first-line options for ovulation induction.
The role of pharmaceutical innovation
At Amagen Pharma Company, we've focused our PCOS formulations on evidence-based combinations — Myogen, Myomet, and Drosse-30 are designed around current clinical guidelines. The aim isn't just symptom management; it's restoring quality of life.
Consult your gynaecologist for personalised treatment plans.